...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Cilostazol for the prevention of acute progressing stroke: A multicenter, randomized controlled trial
【24h】

Cilostazol for the prevention of acute progressing stroke: A multicenter, randomized controlled trial

机译：西洛他唑预防急性进展性中风：一项多中心随机对照试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Progressing stroke is one of the major determinants of outcome after acute ischemic stroke. A pilot randomized controlled trial was conducted to investigate the effect of cilostazol on progressing stroke. Methods: Adult patients with noncardioembolic ischemic stroke within 24 hours after onset were randomized to receive cilostazol 200 mg/day (cilostazol group) or no medication (control group) in addition to the optimum medical treatments (a free radical scavenger plus an antiplatelet agent or an antithrombin agent). The primary endpoints were the rate of progressing stroke, defined as aggravation of the National Institutes of Health Stroke Scale (NIHSS) score by ≥4 points on days 3 and/or 5 and a modified Rankin Scale score of 0 to 1 at 3 months after enrollment. Aggravation caused by systemic complications, edema, hemorrhagic infarction, or recurrent stroke was not considered as progressing stroke. This trial was registered as UMIN000001630. Results: A total of 510 patients were enrolled from 55 institutions in Japan between February 2009 and July 2010. The rate of progressing stroke was 3.2% and 6.3% in the cilostazol and control groups, respectively (P =.143). The modified Rankin Scale score of 0 to 1 at 3 months did not differ between the groups. Conclusions: Cilostazol failed to show a preventive effect against acute progressing stroke. However, the tendency to reduce progressing stroke and the results of stratified analyses may encourage additional studies to clarify the effect of cilostazol in the treatment of acute ischemic stroke.
机译：背景：进行性中风是急性缺血性中风后结局的主要决定因素之一。进行了一项先导性随机对照试验，以研究西洛他唑对进展性中风的影响。方法：成年患者在发作后24小时内发生非心脏栓塞性缺血性卒中，除最佳治疗药物（自由基清除剂加抗血小板药物或抗凝血酶剂）。主要终点指标为中风进展率，定义为美国国立卫生研究院中风量表（NIHSS）评分在第3天和/或第5天加重≥4分，而改良的Rankin量表评分在3个月后为0到1注册。由全身并发症，水肿，出血性梗塞或复发性中风引起的加重不被视为进展性中风。该试验已注册为UMIN000001630。结果：2009年2月至2010年7月间，来自日本55个机构的510名患者入组。西洛他唑组和对照组的中风进展率分别为3.2％和6.3％（P = .143）。两组之间改良的Rankin量表评分在3个月之间为0：1。结论：西洛他唑未能显示出对急性进展性中风的预防作用。但是，减少进行性卒中的趋势和分层分析的结果可能会鼓励进行更多的研究，以阐明西洛他唑在治疗急性缺血性卒中中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号